KLAS: Enterprise resource planning vendors don't have a leg to stand on

No enterprise resource planning (ERP) vendor overwhelmingly satisfies clients more than the others, but with so few options—and none performing well—migrating to a new vendor may not be worth the cost, according to a report published Aug. 11 by market research firm KLAS.

The Orem, Utah-based KLAS interviewed 225 provider organizations, focusing primarily on three players, Lawson, McKesson and Oracle, which were all rated below the KLAS average for healthcare IT.

“Many CIOs describe their experiences with ERP vendors as disappointing and painful,” the report stated. “Providers say they can expect either robust functionality or service and attention — not both.”

According to the report, most hospitals already have a variant of an ERP tool and are somewhat of a captive audience, so vendors have little reason to develop and support their core ERP products. Instead, they focus on developing peripheral modules to address related markets, such as human capital and workforce management, or acquiring new technologies to augment their existing offerings.

“Hospital executives are wishing a vendor would step forward with an integrated stack for ERP, including human capital management, workforce management and business intelligence coupled with functionality and dependable service,” the report concluded. “No one has it all together — yet.”

The top-rated vendor was McKesson with a score of 74.5 out of 100. It was followed by Oracle (71.8) and Lawson (68.6). API Healthcare and MediClick also were highlighted, though neither could be included in the head-to-head comparison with the above vendors, as they provide only some system components.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.